Sinovac Biotech Ltd. Stock News

BEIJING--(BUSINESS WIRE)--Sinovac Biotech Ltd. (NASDAQ:SVA) ("SINOVAC" or the "Company"), a leading provider of biopharmaceutical products in China, today announced that SINOVAC has received on February 8, 2025 a formal court order (the “Order”) from the Privy Council following the previously announced Privy Council Judgment (the “Judgment”) which ruled, among others, that (i) the slate of nomi...

BEIJING--(BUSINESS WIRE)--Sinovac Biotech Ltd. (NASDAQ:SVA) ("SINOVAC" or the "Company"), a leading provider of biopharmaceutical products in China, today announced that the Judicial Committee of the Privy Council in London, England, has ruled that the slate of nominees proposed by a group of shareholders at the 2018 Annual General Meeting was the rightfully elected Board of SINOVAC. The Privy ...

BEIJING--(BUSINESS WIRE)--Sinovac Biotech Ltd. (“SINOVAC” or the “Company”) (NASDAQ: SVA), a leading provider of biopharmaceutical products in China, today kicked off the enrollment for a Phase III clinical trial on a vaccine candidate to prevent HFMD caused by both Enterovirus 71 (EV71) and Coxsackievirus 16 (CA16). Notably, no multivalent vaccines against HFMD have yet been approved for marke...